Chronic Kidney Disease Drugs Market: Global Overview and Forecast (2024-2030)

Chronic Kidney Disease Drugs Market size was valued at USD 13.13 Bn. in 2023 and the total Chronic Kidney Disease (CKD) Drugs revenue is expected to grow by 5.6% from 2024 to 2030, reaching nearly USD 19.22 Bn.
Chronic Kidney Disease Drugs Market Overview:
The Chronic kidney disease occurs when the kidneys get damaged and are unable to filter blood properly. Patients may experience difficulties relating to fluid, electrolytes (minerals necessary for many internal processes), and waste build-up as a result of this poor filtration. Chronic renal disease can sometimes lead to kidney failure. Patients are also at significant risk of developing cardiovascular diseases, such as heart disease and stroke.

It has evolved into a significant public health problem. 15% of adults in the United States, or roughly 37 million individuals, are expected to have CKD. According to figures provided on World Kidney Day, a joint effort of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), kidney disease afflicting over 850 million people globally in 2020. According to statistics, one out of every 10 persons has the chronic renal disease (CKD). The global burden of CKD is growing and is expected to become the fifth leading cause of years of life lost by 2040.

The rising prevalence and incidence of illnesses such as diabetes, hypertension, interstitial nephritis, glomerulonephritis, polycystic kidney disease, and others are some of the primary factors driving the global need for kidney disease medications. The growing incidence of kidney illnesses, as well as the rising need for effective pharmaceuticals for chronic disease diagnostics, are some of the primary drivers driving the growth of the chronic kidney disease (CKD) drug market.To know about the Research Methodology :- Request Free Sample Report
Chronic Kidney Disease Drugs Market Dynamics:
The rising population of Kidney Failures across the globe

Kidney failure is a global public health issue with rising incidence and prevalence, high expenditures, and poor results. There is also a much greater frequency of chronic kidney disease (CKD) in its early stages, with negative effects such as renal function loss, cardiovascular disease (CVD), and premature mortality. Strategies for improving outcomes necessitate a global effort focused on the early stages of CKD.

One of the main factors in the increased prevalence of kidney failure is CKD. If the kidneys are harmed by an inability to control risk factors, recurring kidney infections, or medications or chemicals that are toxic to the kidneys, CKD is more likely to progress to renal failure, especially in older persons. Lower-income and related issues such as food insecurity and a lack of access to excellent health care are also linked to worsening CKD. However, not all people with CKD progress to renal failure. Treatment may decrease the loss of kidney function and delay renal failure if CKD is discovered early. Even with medication, kidney failure might occur in some situations.

According to the National Kidney Foundation (NKD), CKD affects around 15% of the global population, with millions of people dying each year. According to the NKD, emerging nations such as China and India have a large aging population. The number of patients receiving treatment with a kidney transplant or dialysis continues to rise at a pace of 7-9% every year. Women are expected to have a higher prevalence of chronic kidney disease than males (15% versus 12%). Other factors driving market growth include a rising number of patients suffering from hypertension and diabetes.

CKD affects over one-third of the diabetic population and is the leading cause of end-stage kidney failure. Hypertension is mostly caused by high blood pressure, which raises the risk of ESRD considerably. According to the WHO statistics in 2019, around 1.13 million people all across the globe have hypertension. Diabetes and hypertension were responsible for about 75% of kidney failure. Diabetes is the leading cause of severe kidney disease, followed by hypertension, which affects an estimated 1 million people across the globe. As a result, the growing number of individuals suffering from hypertension and diabetes is driving the market growth.

Medication dosing errors

Medication dosing errors are one of the most common drug-related issues in patients with chronic kidney disease (CKD). Many medications, drugs, and their metabolites are eliminated through the kidney. To avoid toxicity, adequate renal function is essential. Pharmacokinetic and pharmacodynamics characteristics are often altered in patients with renal impairment. Renal failure reduces the clearance of medicines removed predominantly by renal filtration.

As a result, when these medications are provided to individuals with compromised renal function, particular care should be undertaken. Despite the necessity of dose modifications in CKD patients, they are often overlooked. Physicians and pharmacists can collaborate to ensure safe medication prescriptions. This process can be difficult and requires a step-by-step strategy to assure efficacy, reduce future damage, and avoid medication nephrotoxicity.

CKD drugs create medication-related complications (MRPs)

Patients with CKD are frequently administered a variety of drugs to manage disease-related comorbidities, decrease disease progression, and reduce morbidity and death rates. However, the prescription regimens of this group are extremely complicated, raising the risk of medication-related complications (MRPs). As a patient's renal function degrades, the kind and amount of drugs they take rises, placing them at a higher risk for MRPs. MRPs have been linked to morbidity, death, and a worse quality of life.
Chronic Kidney Disease Drugs Market Segment Analysis:
By Drug Class, the Calcium channel blockers segment dominated the market in terms of value and volume in 2023 and is expected to maintain its dominance at the end of the forecast period. Calcium channel blockers (CCBs) are a class of antihypertensive drugs with a wide range of pharmacokinetics and therapeutic effects. Calcium channel blockers relieve the symptoms in a wide range of disorders, including coronary artery disease and high blood pressure, etc., and hence, this is driving the segment growth.

The Calcium channel blockers have been widely used in clinical practice because of their antihypertensive capacity. The prevention of renal damage is a critical goal of antihypertensive treatment. This is especially true given the general population's high prevalence of chronic kidney disease (CKD). Recent research has linked CKD to the absence of proper blood pressure regulation, as well as the clustering of additional cardiovascular risk factors found in metabolic syndrome.

It is necessary to understand the abilities of various antihypertensive medicines or their combinations to concurrently regulate blood pressure while protecting the kidney and avoiding the stimulation of metabolic changes. Recent data from the Intervention as a Goal in Hypertension Treatment trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and African American Study of Kidney Disease and Hypertension (AASK) allow the conclusion that calcium channel blockers are effective antihypertensive drugs to be considered alone or in combination with an angiotensin-converting enzyme inhibitor or an angioplasty.

Treatment of high blood pressure (BP) is an important technique for lowering the burden of hypertension-related cardiovascular and renal illnesses. In spite of these well-established notions, hypertension is insufficiently treated globally. Several methods have been recommended to enhance blood pressure management in hypertensive individuals, including

The preferred use of more effective, long-lasting, and well-tolerated antihypertensive medicines to guarantee treatment adherence.

Extensive use of rational, integrated, and synergistic combination medicines, even as first-line therapy, to meet the prescribed blood pressure objectives.

Drugs inhibiting the renin-angiotensin system and calcium channel blockers (CCBs) are effective and safe in lowering BP levels and achieving the recommended BP targets with a good tolerability profile among the possible antihypertensive drug classes currently available for the clinical management of hypertension, both in monotherapy and combination therapy.

CCBs, in particular, has been one of the most commonly used classes of antihypertensive medicines in the last 20 years, owing to their efficiency in lowering blood pressure levels, high tolerability, and substantial evidence of lowering the cardiovascular and renal consequences of hypertension.The ACE Inhibitors segment is expected to grow significantly during the forecast period owing to the rising use of these drugs to cure kidney-related diseases. The benefits of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in lowering the risk of cardiovascular events (CVEs) and postponing the onset of end-stage kidney disease (ESKD) in patients with chronic kidney disease (CKD) are well documented. However, the effectiveness and safety of these medicines in patients with non-dialysis CKD stages 3-5 remain controversial.

Although ACEIs increased the risk of hyperkalemia, cough, and hypotension, they were still superior to ARBs and other antihypertensive medications in terms of preventing renal events, cardiovascular outcomes, cardiovascular death, and all-cause mortality in CKD3-5 patients on non-dialysis. ACEIs outperformed ARBs in decreasing the risk of all-cause death in individuals with advanced diabetic renal disease, but not in kidney events or cardiovascular events. Hence this is driving this segment growth during the forecast period.
Regional Insights:
North America held the largest market share and dominated the market in 2023. It is expected to maintain its dominance at the end of the forecast period. The improved healthcare infrastructure and increased government efforts, which offer attractive reimbursement policies in the country, are the primary drivers driving the market's growth in the United States. According to the American Cancer Society, around 73,750 new occurrences of kidney cancer in the United States in 2020, with roughly 14,830 fatalities from this illness.

According to the source, kidney cancer is one of the top 10 cancers in both men and women. In men, the lifetime chance of having kidney cancer is around 1 in 46 (2.02%). For women, the lifetime risk is roughly 1 in 82 (1.02%). This suggests that the market for kidney disease diagnostics and therapies has significant potential. The market in the United States is expected to grow during the forecast period due to the significant growth in the incidence and prevalence of renal illnesses.

Market participants are also working on introducing new drugs/ medicines to the market. For example, the US Food and Medicine Administration (FDA) authorized Janssen Pharmaceutical's drug INVOKANA (Canagliflozin) in 2019 to lower the risk of end-stage kidney disease and cardiovascular events in Type 2 diabetes and chronic kidney disease patients.

According to a press release from Boehringer Ingelheim and Eli Lilly, the FDA granted fast-track designation in March 2020 for the investigation of the SGLT2 inhibitor empagliflozin by the Boehringer Ingelheim and Eli Lilly Alliance to reduce the risks of renal disease progression and cardiovascular death in adults with chronic kidney disease. As a result, the prevalence of these factors is expected to provide revenue growth to the regional market.

The Asia Pacific region accounted for the highest revenue share of more than 24.00% because of increased spending on healthcare, various government initiatives & awareness campaigns regarding CKD, availability of technologically advanced drugs, and the presence of newly-established state-of-the-art healthcare facilities in the region. High blood pressure and diabetes are the two most common causes of renal damage. The Asia Pacific region is expected to have the most diabetes and hypertension sufferers in the global, closely followed by Africa.The Asia Pacific region is also anticipated to grow at a CAGR of 4.2% throughout the forecast period because of reasons such as an aging population, varied lifestyle stresses, a big population base, better diagnostic quality, and increasing patient affordability. China has proven to be an appealing market for medical products in recent years.

The Chinese government cut the Value Added Tax (VAT) on medical manufacturing enterprises from 13.3% to 13.0% in March 2019. This was expected to benefit domestic medical equipment makers, offsetting the slowdown caused by the trade war between the United States and China.

Several organizations, both domestic and international, are attempting to capitalize on this opportunity by introducing innovative and cheap items to the market. Various corporations' strategic ambitions to develop their operations in unexplored regions have resulted in significant commercial transactions in the nation, contributing to market growth.

In terms of CAGR, the Middle East and Africa are expected to closely follow the Asia Pacific. Among global populations, the African-Middle Eastern ethnicity is the most prone to CKD. The prevalence of CKD is 18-23% of the overall population in African-Middle Eastern nations, which is much higher than the global population.

Socioeconomic variables such as money and access to modern facilities have resulted in significant changes in people's lifestyles, resulting in lifestyle-related ailments such as obesity, cancer, and heart disease. According to the International Diabetes Federation, 55 million adults in the International Diabetes Federation Middle East and North Africa (IDF MENA) area had diabetes in 2019, with the number expected to rise to 108 million by 2045.
Chronic Kidney Disease Drugs Market Scope: Inquire before buying



Chronic Kidney Disease Drugs Market


Report Coverage
Details


Base Year:
2023
Forecast Period:
2024-2030


Historical Data:
2018 to 2023
Market Size in 2023:
US $ 13.13Bn.


Forecast Period 2024 to 2030 CAGR:
5.6%
Market Size in 2030:
US $ 19.22 Bn.


 Segments Covered:
by Drug Class
ACE Inhibitors
Angiotensin-II Receptor Blockers
Calcium Channel Blockers
Beta Blockers
Erythropoiesis-Stimulating Agents (Esas)
Diuretics
Others


by End User
Hospitals
Specialty Clinics



Chronic Kidney Disease Drugs Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)
Key Players are:
1. Keryx Biopharmaceuticals, Inc. (US)
2. DiaMedica Therapeutics Inc.(US)
3. AbbVie, Inc.(US)
4. Allergan plc.(US)
5. Amgen Inc.(US)
6. Kidney Fibrosis(US)
7. Allena Pharmaceuticals Inc.(US)
8. NovaTarg Therapeutics Inc.(US)
9. KBP BioSciences Co Ltd.(US)
10.IC-MedTech Inc.(US)
11.OPKO Health Inc.(US)
12.Q BioMed Inc(US)
13.Unity Biotechnology Inc.(US)
14.KBP BioSciences Co Ltd(US)
15.FibroGen(US)
16.Johnson & Johnson(US)
17.Akebia Therapeutics, Inc.(US)
18.Pfizer, Inc.(US)
19.Kissei Pharmaceutical Co., Ltd. (Japan)
20.Astellas Pharma Inc.(Japan)
21.Taisho Pharmaceutical Holdings Co Ltd.(Japan)
22.GlaxoSmithKline plc.(UK)
23.AstraZeneca plc(UK)
24.Sanofi S.A.(France)
25.Les Laboratoires Servier SAS(France)

FAQs:

1. Which is the potential market for Chronic Kidney Disease (CKD) Drugs in terms of the region?
Ans. North America is the potential market for Chronic Kidney Disease (CKD) Drugs in terms of the region.

2. What are the restraints for new market entrants?
Ans. The key restraint in the market is Medication dosing errors.

3. What is expected to drive the growth of the Chronic Kidney Disease Drugs Market in the forecast period?
Ans. A major driver in the Chronic Kidney Disease Drugs Market is The rising population of Kidney Failures across the globe.

4. What is the projected market size & growth rate of the Chronic Kidney Disease Drugs Market?
Ans. Chronic Kidney Disease Drugs Market size was valued at USD 13.13 Bn. in 2023 and the total Chronic Kidney Disease (CKD) Drugs revenue is expected to grow by 5.6% from 2024 to 2030, reaching nearly USD 19.22 Bn.

5. What segments are covered in the Chronic Kidney Disease Drugs Market report?
Ans. The segments covered are Drug Class, End User, and Region.